https://www.selleckchem.com/products/sgi-110.html
58; 95% confidence interval [CI], 0.41-0.81; P.01), while BVS had a similar risk of MACE compared with BMS (adjusted OR, 0.91; 95% CI, 0.55-1.52; P=.72). When compared with DES, BVS had a similar risk of MACE (adjusted OR, 1.45; 95% CI, 0.83-2.53; P=.19). In patients with BVS implantation, the risk of the composite outcome of MACE at 3 years was not significantly different when compared with patients with BMS or first-generation DES implantation. In patients with BVS implantation, the risk of the composite outcome of MACE at 3 years